GILD · News · 20260910N

Product / Drug Pipeline Progress

GILEAD SCIENCES, INC. · 2026-09-10 · Importance 31 · Surprise 42

Gilead’s pipeline is entering an execution and prioritization phase across HIV, oncology and inflammation. Chief Medical Officer Dietmar Berger described portfolio expansion through internal development and acquisitions. The company is focusing on advancing catalysts in HIV, oncology and cell therapy while translating recent pipeline investments into commercial growth.